SCHEMBL9909365

SCHEMBL9909365

COc1cccc(C(Cc2ccc(C)c(C)c2)c2ccc(C=O)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MTNR1A P48039 6/20 0.40
MTNR1B P49286 6/20 0.40
PDE4A P27815 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
CASR P41180 2/20 0.38
TAAR1 Q96RJ0 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP2A6 P11509 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909350 0.83 S1PR1 (0.43)
SCHEMBL9275109 0.83 MTNR1A (0.41) NPC1RAB9ATDP1MTNR1AMTNR1B
SCHEMBL9112568 0.81 NPC1 (0.37) NPC1RAB9ATDP1MTNR1AMTNR1B
SCHEMBL9909385 0.81 S1PR1 (0.50) NPC1MTNR1AMTNR1BCASRALDH1A1
SCHEMBL9112140 0.79 CHRM2 (0.45) MTNR1AMTNR1BCHRM2CHRM1CHRM3
SCHEMBL10061463 0.76 S1PR1 (0.51)
SCHEMBL9106787 0.76 CCKAR (0.48) MTNR1AMTNR1BL3MBTL1
SCHEMBL27993059 0.74 CASR (0.59) MTNR1AMTNR1BPDE4ACASRTAAR1
SCHEMBL9111995 0.72 TAAR1 (0.42) CASRTAAR1ADORA2AADORA1L3MBTL1
SCHEMBL9111043 0.72 TAAR1 (0.42) MTNR1AMTNR1BCASRTAAR1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142640-A1 ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 US disclosed
WO-2012074921-A1 ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142640-A1 ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 NPC1 358/4885RAB9A 2324/4885TDP1 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.